Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

Novo Nordisk (NYSE: NVO) is a big name in diabetes care and weight loss. And that's the primary reason people invest in the business today: the lucrative opportunities it has in those areas of ...

New digital health partners Novo Nordisk and Glooko have released their first joint diabetes-focused app. The Cornerstones4Care (C4C) Powered by Glooko mobile app aims to help people manage their ...

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure ...

As a pioneer in diabetes care, Novo has been in the business for more than 85 years and claims 30% of the $50 billion-plus diabetes treatment market and roughly half of the $20 billion insulin market.

Given Novo Nordisk's laser-like focus on developing new therapies to treat type 2 diabetes and obesity, like its blockbuster drugs Ozempic and Wegovy, the likely intent of this deal is to seed its ...

Vertex Pharmaceuticals is different from Novo Nordisk in several ways. The two companies could compete against each other in the future. Vertex is a better pick than Novo right now for one key reason.

It’s taken as a daily injection and is approved under the brand name Victoza to treat diabetes in adults and children ages 10 ...

Ozempic maker Novo Nordisk on Wednesday said data showed its ... Amycretin targets the same GLP-1 hormone as other weight loss and diabetes drugs like Novo’s Ozempic and Wegovy and Lilly ...

New digital health partners Novo Nordisk and Glooko have released their first joint diabetes-focused app. The Cornerstones4Care (C4C) Powered by Glooko mobile app aims to help people manage their ...